Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IN 115314

Next Previous
Drug Profile

IN 115314

Alternative Names: CJ-15314; IN-115314; IN-A002

Latest Information Update: 29 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CJ HealthCare
  • Developer HK inno.N
  • Class Anti-inflammatories; Antirheumatics; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Dermatitis

Most Recent Events

  • 18 Jul 2025 HK inno.N plans a phase II trial for Atopic dermatitis in July 2025 (Topical, Ointment) (NCT07073677)
  • 17 Mar 2025 Ministry of Food and Drug Safety (MFDS) approves IND application for IN 115314 in Atopic dermatitis in South Korea (Topical, ointment) (HK inno.N, April 2025)
  • 28 Mar 2024 Phase I clinical development in Rheumatoid arthritis is ongoing in South Korea (PO) (HK inno.N pipeline, March 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top